Search research articles
Contact Us
Filters
Showing results (31-40 of 95) with videos related to
Page
of 10
Sort By:
Integrative Biology : Quantitative Biosciences From Nano to Macro
|
May 23, 2015
MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells
Chorom Pak, Natalie S Callander, Edmond W K Young, et al.
Molecular Cancer
|
July 8, 2010
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells
Stephanie Markovina, Natalie S Callander, Shelby L O'Connor, et al.
Molecular Cancer Research : MCR
|
August 19, 2008
Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells
Stephanie Markovina, Natalie S Callander, Shelby L O'Connor, et al.
Contemporary Clinical Trials Communications
|
June 6, 2022
A biobehavioral intervention to enhance recovery following hematopoietic cell transplantation: Protocol for a feasibility and acceptability randomized control trial
Andrew Kirvin-Quamme, Meredith E Rumble, Lisa Cadmus-Bertram, et al.
Experimental Hematology
|
February 26, 2005
MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells
Yasuo Oba, Jun Won Lee, Lori A Ehrlich, et al.
Blood Cancer Journal
|
February 5, 2025
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
Luciano J Costa, Eva Medvedova, Binod Dhakal, et al.
Blood Cancer Journal
|
April 23, 2025
Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy
Susan Bal, Tylan Magnusson, Gayathri Ravi, et al.
The Lancet. Oncology
|
October 27, 2009
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S Vincent Rajkumar, Susanna Jacobus, Natalie S Callander, et al.
Human Immunology
|
December 29, 2004
Severe, late-onset graft-versus-host disease in a liver transplant recipient documented by chimerism analysis
Marilyn S Pollack, Kermit V Speeg, Natalie S Callander, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 6, 2016
Multiple Myeloma in Pregnancy--A Review of the Literature and a Case Series
Artur Jurczyszyn, Magdalena Olszewska-Szopa, Adam S Vesole, et al.
Page
of 10
Search research articles
Search
Showing results (31-40 of 95) with videos related to
Sort By:
Page
of 10
Integrative Biology : Quantitative Biosciences From Nano to Macro
|
May 23, 2015
MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells
Chorom Pak, Natalie S Callander, Edmond W K Young, et al.
Molecular Cancer
|
July 8, 2010
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells
Stephanie Markovina, Natalie S Callander, Shelby L O'Connor, et al.
Molecular Cancer Research : MCR
|
August 19, 2008
Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells
Stephanie Markovina, Natalie S Callander, Shelby L O'Connor, et al.
Contemporary Clinical Trials Communications
|
June 6, 2022
A biobehavioral intervention to enhance recovery following hematopoietic cell transplantation: Protocol for a feasibility and acceptability randomized control trial
Andrew Kirvin-Quamme, Meredith E Rumble, Lisa Cadmus-Bertram, et al.
Experimental Hematology
|
February 26, 2005
MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells
Yasuo Oba, Jun Won Lee, Lori A Ehrlich, et al.
Blood Cancer Journal
|
February 5, 2025
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
Luciano J Costa, Eva Medvedova, Binod Dhakal, et al.
Blood Cancer Journal
|
April 23, 2025
Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy
Susan Bal, Tylan Magnusson, Gayathri Ravi, et al.
The Lancet. Oncology
|
October 27, 2009
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S Vincent Rajkumar, Susanna Jacobus, Natalie S Callander, et al.
Human Immunology
|
December 29, 2004
Severe, late-onset graft-versus-host disease in a liver transplant recipient documented by chimerism analysis
Marilyn S Pollack, Kermit V Speeg, Natalie S Callander, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 6, 2016
Multiple Myeloma in Pregnancy--A Review of the Literature and a Case Series
Artur Jurczyszyn, Magdalena Olszewska-Szopa, Adam S Vesole, et al.
Page
of 10